Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction

American Journal of Cardiology

Volumn 87, Issue 6, 2001, Pages 771-774

  Bybee, Kevin A ^a   Wright, R Scott ^a,b   Williams, Brent A ^a,b   Murphy, Joseph G ^a   Holmes Jr , David R ^a   Kopecky, Stephen L ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Physician Alliance for Clinical Trials Rochester   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSIDE; HEPARIN; LIDOCAINE; NITRATE; STATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART REINFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THROMBOCYTE AGGREGATION;

AGED; ANTILIPEMIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0035869144     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01501-0     Document Type: Article

References (20)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE)
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Cholesterol lowering - Should it continue to be the last thing we do?
5. Hydroxymethylglutaryl coenzyme. A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae
6. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
7. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
8. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia
9. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
10. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
11. Abnormalities of blood rheology in familial hypercholesterolemia: Effects of treatment
12. Lovastatin therapy in hypercholesterolemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology
13. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
14. 2+ and membrane dynamics in patients with primary hypercholesterolemia: Effects of pravastatin
15. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients
16. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease
17. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
18. Antiatherothrombotic properties of statins
19. Statins do more than lower cholesterol
20. WHO criteria for diagnosis of acute myocardial infarction